These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16306032)

  • 21. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.
    Narang VS; Lulla A; Malhotra G; Purandare S
    J Clin Pharmacol; 2005 Mar; 45(3):265-74. PubMed ID: 15703362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.
    Bruno R; Regazzi MB; Ciappina V; Villani P; Sacchi P; Montagna M; Panebianco R; Filice G
    Clin Pharmacokinet; 2001; 40(9):695-700. PubMed ID: 11605717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.
    Mukherjee A; Singla M; Velpandian T; Sirohiwal A; Vajpayee M; Singh R; Kabra SK; Lodha R
    Indian Pediatr; 2014 Mar; 51(3):191-7. PubMed ID: 24736906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F; Reliquet V; Ferré V; Arvieux C; Hascoet C; Bellein V; Besnier JM; Breux JP; Garré M; May T; Molina JM; Perré P; Raguin G; Rozenbaum W; Zucman D
    Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
    Chokephaibulkit K; Plipat N; Cressey TR; Frederix K; Phongsamart W; Capparelli E; Kolladarungkri T; Vanprapar N
    AIDS; 2005 Sep; 19(14):1495-9. PubMed ID: 16135903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
    Byakika-Tusiime J; Chinn LW; Oyugi JH; Obua C; Bangsberg DR; Kroetz DL
    PLoS One; 2008; 3(12):e3981. PubMed ID: 19096711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
    Corbett AH; Hosseinipour MC; Nyirenda J; Kanyama C; Rezk NL; Mkupani P; Sichali D; Tien H; Kashuba AD; Mwansambo C; Weigel R; Kazembe P
    Antivir Ther; 2010; 15(1):83-90. PubMed ID: 20167994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.
    Sabo JP; Lamson MJ; Leitz G; Yong CL; MacGregor TR
    AAPS PharmSci; 2000; 2(1):E1. PubMed ID: 11741217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition.
    Monif T; Tippabhotla SK; Garg M; Singla AK; Vijan T
    Int J Clin Pharmacol Ther; 2006 Jun; 44(6):276-83. PubMed ID: 16800100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
    Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
    Idigbe EO; Adewole TA; Eisen G; Kanki P; Odunukwe NN; Onwujekwe DI; Audu RA; Araoyinbo ID; Onyewuche JI; Salu OB; Adedoyin JA; Musa AZ
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):65-9. PubMed ID: 16123684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
    Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
    Taylor S; van Heeswijk RP; Hoetelmans RM; Workman J; Drake SM; White DJ; Pillay D
    AIDS; 2000 Sep; 14(13):1979-84. PubMed ID: 10997403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
    Yong CL; Gathe JC; Knecht G; Orrell C; Mallolas J; Podzamczer D; Trottier B; Zhang W; Sabo JP; Vinisko R; Drulak M; Quinson AM
    HIV Clin Trials; 2017; 18(5-6):189-195. PubMed ID: 29210627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Rao Thudi N; Koundinya Tippabhotla S; Khuroo A; Marwah A; Kumar Shrivastav V; Tandon M; Raghuvanshi R; Biswal S
    Clin Ther; 2007 Dec; 29(12):2677-84. PubMed ID: 18201583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
    Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
    HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of nevirapine in Thai HIV-infected patients.
    Wattanakul T; Avihingsanon A; Manosuthi W; Punyawudho B
    Antivir Ther; 2014; 19(7):651-60. PubMed ID: 24504545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.
    Portsmouth SD; Osorio J; McCormick K; Gazzard BG; Moyle GJ
    HIV Med; 2005 May; 6(3):185-90. PubMed ID: 15876285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.